(JPM) Signs Clinical Study Agreement with The Applied Science University (ASU)
16/04/2019
JPM as a Quality & Research company signed an agreement with the AUS to follow up about 700 patients revealed to need treatment for Dyslipidaemia, according to the results of a recent study (2018) carried out in cooperation with the General Practitioner Society.
The agreement involves preparing and executing protocols aiming to achieve the following main objectives;
- A meta-analysis of the available Jordanian studies on Dyslipidaemia
- Validation of the Adequacy of ARAGEN devices for measuring lipids.
- Study of the Economic role of the pharmacist in monitoring and controlling of Dyslipidaemia, Hypertension, Diabetes and overweight
- The use of Montelukast in Asthma, COPD.
- Study of the resistance of Fluoroquinolones compared to the resistance of Cephalosporines among Jordanians.
The agreement was signed by Dr Adnan Badwan the General Director of JPM and Prof. Mahfouz Joudeh the President of ASU in the presence of Prof. Eman Al Basheety the Dean of Pharmacy school at ASU, and Dr Taghreed Al Barqawi the Executive Marketing Manager at JPM. and Dr Wesam Alsoud the Scientific manager at JPM.